The development of pharmacological weight loss methods has been problematic, Rimonabant, a CB1R antagonist, showed promise in laboratory studies, but clinical trials were discontinued due to serious psychiatric side effects,53,54 although ongoing studies suggest that peripherally restricted CB1R antagonists may provide therapeutic benefits in obesity without such psychiatric side effects.43–46. Here, CNR1 is linked to obesity disorder.